Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Nuvalent (NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat on December 3, 2024, at 3:30 p.m. ET in NYC. The presentation will be accessible via live webcast on Nuvalent's website investor section and will remain available for 30 days afterward.

News Market Reaction – NUVL

+0.71%

1 alert

+0.71% News Effect

On the day this news was published, NUVL gained 0.71%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

11/26/2024 - 06:52 AM

CAMBRIDGE, Mass, Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36^th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m. ET in NYC.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302316455.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent (NUVL) presenting at the Piper Sandler Healthcare Conference 2024?

Nuvalent (NUVL) will present at the Piper Sandler Healthcare Conference on December 3, 2024, at 3:30 p.m. ET in NYC.

How can I watch Nuvalent's (NUVL) presentation at the Piper Sandler Conference?

The presentation can be viewed via live webcast in the Investors section of Nuvalent's website (www.nuvalent.com) and will be archived for 30 days after the event.